Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2010

01-07-2010 | Translational Research and Biomarkers

Altered Expression of E-cadherin by Hepatocyte Growth Factor and Effect on the Prognosis of Nasopharyngeal Carcinoma

Authors: Li-qiong Xie, MPhil, Li-juan Bian, MPhil, Zhi Li, PhD, Yang Li, PhD, Zhi-xun Li, MBBS, Bin Li, MBBS

Published in: Annals of Surgical Oncology | Issue 7/2010

Login to get access

Abstract

Background and Purpose

Hepatocyte growth factor (HGF)-related E-cadherin expression and prognosis of patients with nasopharyngeal carcinoma (NPC) are not fully understood. This study investigated HGF-induced altered expression of E-cadherin and the relationship between prognosis and modulation of E-cadherin by HGF in NPC.

Methods

135 cases of NPC were collected, and expression of HGF, c-Met, and E-cadherin in tissue microarray was evaluated by immunohistochemical staining. Correlation between immunostainings and clinicopathological parameters, as well as the follow-up data of patients, was analyzed statistically. The association and alteration of E-cadherin by HGF treatment in NPC cell lines were evaluated by immunocytochemical staining, Western blot, and invasion assay.

Results

Both high HGF expression in tumor cells (62.9%, 85/135 cases) and nonmembranous E-cadherin expression (61.5%, 83/135 cases) were significantly associated with advanced clinical stage, lymph node metastasis, and worse prognosis of NPC patients. However, only abnormal E-cadherin expression (P = 0.001) and lymph node metastasis (P = 0.004) emerged as strong independent prognostic factors for overall survival of NPC patients. In vitro, exogenous HGF decreased and internalized E-cadherin expression from cell membrane to cytoplasm, with obvious cellular morphological change. HGF-treated NPC cells exhibited significantly enhanced invasive ability in Matrigel matrix-coated Transwell chamber assay.

Conclusion

HGF may contribute to cell invasion in NPC by modulating E-cadherin-mediated cell–cell adhesion through downregulation and internalization of E-cadherin. Altered expression of E-cadherin by HGF is a valuable predictor for prognostic evaluation of NPC patients.
Literature
1.
2.
Farias TP, Dias FL, Lima RA, Kligerman J, de Sa GM, Barbosa MM, et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:794–9.CrossRefPubMed
3.
Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet. 1995;345:293–5.CrossRefPubMed
4.
Liu ZX, Yu CF, Nickel C, Thomas S, Cantley LG. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J Biol Chem. 2002;277:10452–8.CrossRefPubMed
5.
Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 2006;147:2557–66.CrossRefPubMed
6.
Steffen M, Zuehlke I, Scherdin U. Motility factors identified in supernatants of human cholangiocarcinoma cell lines. Int J Oncol. 2001;18:1107–12.PubMed
7.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–25.CrossRefPubMed
8.
Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 2002; 62:589-96.PubMed
9.
Li Z, Lin SX, Liang HZ, He JH. Expression of hepatocyte growth factor/c-Met system in nasopharyngeal carcinoma and its biological significance. Zhonghua Bing Li Xue Za Zhi. 2005;34:75–9.PubMed
10.
Gumbinera BM. Regulation of cadherin adhesive activity. J Cell Biol. 2000;148:399–404.CrossRef
11.
Yagi T, Takeichi M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev. 2000;14:1169–80.PubMed
12.
Palacios F, Price L, Schweitzer J, Collard JG, D’Souza-Schorey C. An essential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration. EMBO J. 2001;20:4973–86.CrossRefPubMed
13.
Anderson MR, Harrison R, Atherfold PA, Campbell MJ, Darnton SJ, Obszynska J, et al. Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin Cancer Res. 2006;12:5936–43.CrossRefPubMed
14.
Tannapfel A, Wittekind C, Yasui W, Yokozaki H, Tahara E. Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines. Virchows Arch. 1994;425:139–44.CrossRefPubMed
15.
Miura H, Nishimura K, Tsujimura A, Matsumiya K, Matsumoto K, Nakamura T, et al. Effects of hepatocyte growth factor on E-cadherin-mediated cell-cell adhesion in DU145 prostate cancer cells. Urology. 2001;58:1064–9.CrossRefPubMed
16.
Min H, Hong M, Ma J, et al. A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994;30:1037–42.PubMed
17.
Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 2001;10:657–62.CrossRefPubMed
18.
Kim CH, Kim JH, Kahng H, Choi EC. Change of E-cadherin by hepatocyte growth factor and effect on prognosis of hypopharyngeal carcinoma. Ann Surg Oncol. 2007;14:1565–74.CrossRefPubMed
19.
Li Z, Bian LJ, Li Y, Liang YJ, Liang HZ. Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis. Pathol Res Pract. 2009;205:542–50.CrossRefPubMed
20.
Han SU, Lee HY, Lee JH, et al. Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg. 2005;242:676–83.CrossRefPubMed
21.
Nakamura Y, Matsubara D, Goto A, et al. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci. 2008;99:14–22.CrossRefPubMed
22.
Maroni P, Bendinelli P, Matteucci E, Desiderio MA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis. 2007;28:267–79.CrossRefPubMed
23.
Zhou HY, Wan KF, Ip CK, Wong CK, Mak NK, Lo KW, et al. Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett. 2008;582:3415–22.CrossRefPubMed
24.
Spix JK, Chay EY, Block ER, Klarlund JK. Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res. 2007;313:3319–25.CrossRefPubMed
25.
Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994;54:1630–3.PubMed
26.
Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol. 1994;125:1327–40.CrossRefPubMed
27.
Wu H, Lotan R, Menter D, Lippman SM, Xu XC. Expression of E-cadherin is associated with squamous differentiation in squamous cell carcinomas. Anticancer Res. 2000;20:1385–90.PubMed
28.
Chang HW, Chow V, Lam KY, Wei WI, Yuen A. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer. 2002;94:386–92.CrossRefPubMed
29.
Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene. 2001;20:8125–35.CrossRefPubMed
30.
Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65:5991–5; discussion 5995.CrossRefPubMed
31.
Kondo M, Cubillo E, Tobiume K, et al. A role for Id in the regulation of TGF-beta-induced epithelial-mesenchymal transdifferentiation. Cell Death Differ. 2004;11:1092–101.CrossRefPubMed
32.
Horiguchi K, Shirakihara T, Nakano A, Imamura T, Miyazono K, Saitoh M. Role of Ras signaling in the induction of snail by transforming growth factor-beta. J Biol Chem. 2009;284:245–53.CrossRefPubMed
33.
Shirakihara T, Saitoh M, Miyazono K. Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell. 2007;18:3533–44.CrossRefPubMed
34.
Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008;25:621–8.CrossRefPubMed
35.
Grotegut S, von Schweinitz D, Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J. 2006;25:3534–45.CrossRefPubMed
36.
Hiscox S, Jiang WG. Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Res. 1999;19:509–17.PubMed
37.
Ye M, Hu D, Tu L, et al. Involvement of PI3 K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci. 2008;49:497–504.CrossRefPubMed
38.
Reshetnikova G, Troyanovsky S, Rimm DL. Definition of a direct extracellular interaction between Met and E-cadherin. Cell Bio Int. 2007;31:366–73.CrossRef
Metadata
Title
Altered Expression of E-cadherin by Hepatocyte Growth Factor and Effect on the Prognosis of Nasopharyngeal Carcinoma
Authors
Li-qiong Xie, MPhil
Li-juan Bian, MPhil
Zhi Li, PhD
Yang Li, PhD
Zhi-xun Li, MBBS
Bin Li, MBBS
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0922-6

Other articles of this Issue 7/2010

Annals of Surgical Oncology 7/2010 Go to the issue

Colorectal Cancer

Downstaging Without Complete Pathologic Response After Neoadjuvant Treatment Improves Cancer Outcomes for cIII but not cII Rectal Cancers

Hepatobiliary Tumors

Survival Analysis of Intrahepatic Cholangiocarcinoma After Resection

Gastrointestinal Oncology

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

Healthcare Policy and Outcomes

Surgical Oncology Trials and Surgeons in the Real World!

Translational Research and Biomarkers

Which Method to Deliver Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin? An Experimental Comparison of Open and Closed Techniques

Hepatobiliary Tumors

Number of Positive Lymph Nodes Independently Determines the Prognosis After Resection in Patients with Gallbladder Carcinoma